Connect Biopharma Holdings Limited Increase (Decrease) in Accrued Liabilities
Connect Biopharma Holdings Limited (CNTB) reported Increase (Decrease) in Accrued Liabilities of $2.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-12
- Connect Biopharma Holdings Limited increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $3.06M, a 340.43% increase year-over-year.
- Connect Biopharma Holdings Limited increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$404.00K.
- Connect Biopharma Holdings Limited increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.23M.
- Connect Biopharma Holdings Limited increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $999.00K.
- Connect Biopharma Holdings Limited increase (decrease) in accrued liabilities for fiscal 2025 was $3.36M.
- Connect Biopharma Holdings Limited increase (decrease) in accrued liabilities for fiscal 2024 was -$1.68M.
- Connect Biopharma Holdings Limited increase (decrease) in accrued liabilities for fiscal 2023 was -$6.08M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.66M 10-Q · filed 2026-08-12 | $4.88M derived: sum of 3 quarters · filed 2026-08-12 | $5.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$404.00K 10-Q · filed 2026-05-12 | $1.82M derived: sum of 2 quarters · filed 2026-05-12 | $2.82M derived: sum of 3 quarters · filed 2026-05-12 | $3.52M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.23M derived: sum of 2 quarters · filed 2026-03-31 | $3.92M derived: sum of 3 quarters · filed 2026-08-12 | $3.36M 10-K · filed 2026-03-31 |
| 2025-09-30 | $999.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.69M derived: sum of 2 quarters · filed 2026-08-12 | $1.13M 10-Q · filed 2025-11-12 | $114.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $695.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $131.00K 10-Q · filed 2026-08-12 | -$885.00K derived: sum of 3 quarters · filed 2026-08-12 | -$967.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$564.00K 10-Q · filed 2026-05-12 | -$1.58M derived: sum of 2 quarters · filed 2026-05-12 | -$1.66M derived: sum of 3 quarters · filed 2026-05-12 | -$2.97M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.10M derived: sum of 2 quarters · filed 2026-03-31 | -$2.40M derived: sum of 3 quarters · filed 2026-03-31 | -$1.68M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.39M derived: sum of 2 quarters · filed 2025-11-12 | -$661.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$579.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $725.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$6.08M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |